Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients

Cancer Research

Volumn 61, Issue 16, 2001, Pages 5964-5968

  Andersen, Mads Hald ^a   Pedersen, Lars Ø ^a   Capeller, Barbara ^a   Bröcker, Eva Bettina ^a   Becker, Jurgen C ^a   Straten, Perthor ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SURVIVIN; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035881885     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Tumor antigens recognized by T lymphocytes
2. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting
3. Prognostic significance of survivin expression in diffuse large B-cell lymphomas
4. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma
5. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line
6. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma
7. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer
8. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer
9. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides
10. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients
11. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination
12. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
13. Phenotypic analysis of antigen-specific T lymphocytes
14. Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients
15. Biomagnetic isolation of antigen-specific CD8+ T cells usable in immunotherapy
16. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL
17. Generation of human-melanoma specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines
18. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients
19. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
20. In situ T-cell responses against melanoma comprise high numbers of locally expanded T-cell clonotypes
21. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides
22. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis
23. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma
24. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients
25. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
26. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
27. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: Implications for immunotherapy
28. Immune selection after antigen-specific immunotherapy of melanoma
29. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with down-regulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
30. Inhibition of melanoma tumor growth in vivo by survivin targeting
31. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
32. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers
33. Molecular basis of spontaneous regression of neuroblastoma: Role of neurotrophic signals and genetic abnormalities